[ad_1]
One study has shown that newer types of combined oral contraceptives – containing both estrogen and progestin – can reduce the risk of ovarian cancer in young women.
The study, published by the BMJ, showed that this positive effect was reinforced with longer periods of use and persisted for several years after stopping treatment, providing significant comfort to women.
At least 100 million women around the world use hormonal contraception every day.
Previous research has shown a reduction in the risk of ovarian cancer in women who take combined oral contraceptives, but most evidence relates to the use of older products, containing higher levels of oral contraceptives. 39, estrogens and older progestins.
Women who use newer oral contraceptives and other hormonal contraceptive methods also want to know if they are likely to benefit from the same benefit.
Researchers from the University of Aberdeen in Scotland and The University of Copenhagen in Denmark has studied the influence of new hormonal contraceptives (combined products and compounds composed solely of progestins) on the overall and specific types of ovarian cancer in women of childbearing age .
They analyzed the data of nearly 1.9 million Danish women between the ages of 15 and 49 between 1995 and 2014.
Women were classified as never current users, current or recent users (up to one year after stopping use) or former users (more than one year after the start). stopping the use) of different hormonal contraceptives.
Most (86%) of the hormonal contraceptives were combined oral products, according to the researchers.
After taking into account several factors, including age and parity, the researchers found that the number of ovarian cancer cases was highest among women who had never used any drugs. hormonal contraception – 7.5 per 100,000 person-years.
Among women who have ever used hormonal contraception, the number of cases of ovarian cancer was 3.2 per 100,000 person-years.
There was no strong evidence to suggest a protective effect in women who used products containing only progestins, although the researchers point out that few women used these products exclusively.
The reduced risk for combination products was observed with almost all types of ovarian cancer and there was little evidence of significant differences between products containing different types of progestins.
Similar results were also observed in women followed up to their first contraceptive-type change.
On the basis of these figures, the researchers said that hormonal contraception prevented about 21% of ovarian cancers in this group of women.
(This story has not been changed by Business Standard staff and is generated automatically from a syndicated feed.)
[ad_2]
Source link
